Clinical Cancer Research

Table of Contents

October 1, 2014 • Volume 20 • Number 19

Highlights of This Issue 4975

SPECIAL FEATURES

Editorial

4977 AACR Cancer Progress Report 2014: Transforming Lives Through Research
Jesse Potash and Kenneth C. Anderson

Policy Statement

4978 Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research
Charles L. Sawyers and Laura J. van ‘t Veer

CCR Translations

4982 The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
Antoni Ribas and Paul C. Tumeh
See related article, p. 5064

CCR New Strategies

4985 New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach
Amer M. Zeidan and Steven D. Gore

CCR Perspectives in Drug Approval

4994 FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Geoffrey Kim, Amy E. McKee, Yang-Min Ning, Maitreyee Hazarika, Marc Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne Marie Russell, Sarah Pope Mikinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Anna Ibrahim, Robert Justice, and Richard Pazdur

Molecular Pathways

5001 Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination
Teresa Ezponda and Jonathan D. Licht

CANCER THERAPY: CLINICAL

5009 A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

5023 Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

5032 Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, and Anthony W. Tolcher
5041 Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

5052 Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Yoshihiro Ohue, Koji Kurose, Yu Mizote, Hirofumi Matsumoto, Yumi Nishio, Midori Isobe, Minoru Fukuda, Akiko Uenaka, Mikio Oka, and Eiichi Nakayama

PERSONALIZED MEDICINE AND IMAGING

5054 Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Janis M. Taube, Alison Klein, Julie R. Brahmer, Haiying Xu, Xiaoyu Pan, Jung H. Kim, Lieping Chen, Drew M. Pardoll, Suzanne L. Topalian, and Robert A. Anders
See related commentary, p. 4982

5064 Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
David Karnak, Carl G. Engelke, Leslie A. Parsels, Tasneem Kausar, Dongping Wei, Jordan R. Robertson, Katherine B. Marsh, Mary A. Davis, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence, and Meredith A. Morgan

5075 Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma
Audrey Lamora, Julie Talbot, Gwenola Bougras, Jérôme Amiaud, Marion Leduc, Julie Chesneau, Julien Taurelle, Verena Streising, Marie Cécile Le Deley, Marie Françoise Heymann, Dominique Heymann, Françoise Redini, and Franck Verrecchia

BIOLOGY OF HUMAN TUMORS

5113 Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok, Jaeyu Chen, Zijian Y. Xu-Monette, Alexandar Tzankov, Ganrajra C. Manyam, Ling Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youl Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hi, William W.L. Choi, J. Han van Krieken, Jooryung Huh, Xiaoying Zhao, Maurilio Ponzoni, André J.M. Ferrer, Francesco Bertoni, John P. Farnen, Michael B. Møller, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros, and Ken H. Young

CANCER THERAPY: PRECLINICAL

5124 Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival
Snehal Dabir, Amy Kluge, Adam Kresak, Michael Yang, Pingfu Fu, Bernd Groner, Gary Wildey, and Afshin Dowlati

5133 The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients
Yonggang He, Jian Gu, Sara Strom, Christopher J. Logothetis, Jeri Kim, and Xifeng Wu

5140 Tumor Stromal Phenotypes Define VEGF Sensitivity—Letter

LETTERS TO THE EDITOR
5141  Tumor Stromal Phenotypes Define VEGF Sensitivity—Response

CORRECTION
5142  Correction: A Severe Combined Immunodeficient–hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma

ABOUT THE COVER
The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m² cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue.
Clinical Cancer Research

20 (19)


| Updated version | Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/20/19 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/20/19. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |